LCS
CGTX icon

Levin Capital Strategies’s Cognition Therapeutics CGTX Stock Holding History

Levin Capital Strategies’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$54.6K – 239
2024
Q1 		$54.6K Buy
+30,000
New +$61.9K 0.01% 226

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Levin Capital Strategies's CGTX Position: Q2 2024 in Review

Levin Capital Strategies sold out of Cognition Therapeutics (CGTX) in Q2 2024, closing a stake of 30,000 shares — an estimated $54.6K sold.

Levin Capital Strategies first reported a position in CGTX in Q1 2024 and held it in 1 quarter. The position peaked at $54.6K in Q1 2024. 46 funds tracked by Wall St. Rank hold CGTX as of Q2 2024.

  • Levin Capital Strategies reported no remaining Cognition Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 30,000 Cognition Therapeutics shares in Q2 2024, an estimated $54.6K.
  • Levin Capital Strategies first reported a position in Cognition Therapeutics in Q1 2024 and held it in 1 quarter.
  • Levin Capital Strategies's Cognition Therapeutics position peaked at $54.6K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2024.

Based on Levin Capital Strategies's 13F filing for Q2 2024, filed 7 Aug 2024.